Summit Therapeutics Opens Phase II Study of Ivonescimab Regimens
The global Phase II study will evaluate ivonescimab-based regimens in advanced clear cell renal cell carcinoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Summit Therapeutics Opens Global Phase II Ivonescimab Study
Summit Therapeutics announced the initiation of a multiregional Phase II study of ivonescimab in previously untreated advanced clear cell renal cell carcinoma.